Knockdown of circular RNA hsa_circ_0062270 suppresses the progression of melanoma via downregulation of CDC45

xlomafota13 shared this article with you from Inoreader Knockdown of circular RNA hsa_circ_0062270 suppresses the progression of melanoma via downregulation of CDC45 Via Cellular and Molecular Biology Histol Histopathol. 2021 Dec 21:18412. doi: 10.14670/HH-18-412. Online ahead of print. ABSTRACT BACKGROUND: Although systemic therapies for melanoma have been improved, the 5-year survival rate of this aggressive cancer remains poor. It has been shown that hsa_circ_0062270 was upregulated in patients with melanoma. However, the relevant mechanism of hsa_circ_0062270 in the progression of melanoma remains unclear. METHODS: The CCK-8, EdU staining, flow cytometry, and transwell assays were used to determine the viability, proliferation, apoptosis and invasion in melanoma cells. An in vivo animal study was performed finally. RESULTS: The level of hsa_circ_0062270 was significantly upregulated in melanoma cells. In addition, hsa_circ_0062270 knockdown markedly inhibited the viability, proliferation, invasion and promoted the apoptosis of melanoma cells. Cell division cycle protein 45 (CDC45) is the host gene of hsa_circ_0062270 , and downregulation of hsa_circ_0062270 notably decreased the expression of CDC45 in melanoma cells. Rescue assays confirmed that hsa_circ_0062270 regulated the growth of melanoma cells through CDC45. Moreover, RIP analysis showed that hsa_circ_0062270 interacted with RNA-binding protein (RBP) EIF4A3. Furthermore, in vivo study indicated that knockdown of hsa_circ_0062270 inhibited the melanoma tumor growth in vivo. CONCLUSIONS: Downregulation of hsa_circ_0062270 can inhibit the progression of melanoma through downregulation of CDC45. Our findings provide biological mechanisms for the use of hsa_circ_0062270 as a biomarker for melanoma and potential therapeutic target. PMID:34931691 | DOI:10.14670/HH-18-412 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.